The RELIEF study: Tolerability and efficacy of preservative-free latanoprost in the treatment of glaucoma or ocular hypertension

Misiuk-Hojło, Marta; Pomorska, M; Mulak, Małgorzata; Rękas, Marek; Wierzbowska, Joanna; Prost, M; Wasyluk, J; Lubiński, Wojciech; Podborączyńska–Jodko, Karolina; Romaniuk, W; Kinasz, Renata; Ortyl-Markiewicz, Renata; Mocko, Lucyna; Zaleska-Żmijewska, Anna; Rokicki, Dariusz; Baudouin, Christophe

doi:10.1177/1120672118785280

Cited by 33 publications

(36 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Uusitalo et al have demonstrated a decrease in the occurrence of irritation/burning/stinging, foreign body sensation, tearing, itching, dry eye sensation, blepharitis, corneal/conjunctival fluorescein staining 12 weeks after changing therapy from preserved latanoprost to preservative-free tafluprost [2]. Similar results were received by the RELIEF study in which the tolerability and efficacy following a switch from BAC-preserved latanoprost to preservative-free latanoprost were assessed [3].…”

Section: Discussionmentioning

confidence: 81%

“…This implicates minimization of the side effects of the treatment [1]. However, prostaglandin F2α analogs (PGAs), which are the first-line eye drops used in primary open-angle glaucoma (POAG), commonly cause local side effects such as burning, stinging, foreign body sensation, tearing, or conjunctival hyperemia, especially in patients undergoing long-term treatment [2,3]. These adverse effects not only reduce the quality of life but are also responsible for treatment cessation by the patients.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Effect of Topical Prostaglandin F2α Analogs on Selected Oxidative Stress Parameters in the Tear Film

et al. 2019

View full text Add to dashboard Cite

Background and Objectives: Topically administered antiglaucoma medications, especially those containing benzalkonium chloride (BAC), may cause local adverse effects and compromise ocular surface. The aim of the study was to assess the effect of topical prostaglandin F2α analogs (PGAs): preservative-free latanoprost, BAC-preserved latanoprost, preservative-free tafluprost, and BAC-preserved bimatoprost, on selected oxidative stress parameters in the tear film. Materials and Methods: The patients were divided into five groups: group C (n = 25) control group—subjects who did not use topical antiglaucoma medications, group L (n = 22)—patients using topical preservative-free latanoprost, group L+BAC (n = 25)—patients using topical BAC-preserved latanoprost, group T (n = 19)—patients using topical preservative-free tafluprost, and group B+BAC (n = 17)—patients using topical BAC-preserved bimatoprost. The oxidative stress markers in the tear film samples were evaluated: total protein (TP) concentration, advanced oxidation protein products (AOPP) content, total sulfhydryl (-SH) groups content, the activity of superoxide dismutase (SOD), catalase (CAT), and glutathione peroxidase (GPx), as well as Total Oxidant Status (TOS), Total Antioxidant Response (TAR), and Oxidative Stress Index (OSI). Results: The TP concentrations in the groups L, L+BAC, and B+BAC were statistically significantly higher in comparison with group C. The SOD and CAT activities in the groups L+BAC and B+BAC were statistically significantly higher when compared to group C. As compared to group C, AOPP and TOS were statistically significantly higher in all the study groups. OSI was found to be statistically significantly higher in the groups L+BAC, T, and B+BAC in comparison with group C. Conclusion: Use of topical PGAs by the patients with ocular hypertension or primary open-angle glaucoma is associated with increased oxidative stress in the tear film which is additionally exacerbated by the presence of BAC in the formulation.

show abstract

Section: Discussionmentioning

confidence: 81%

Section: Introductionmentioning

confidence: 99%

Effect of Topical Prostaglandin F2α Analogs on Selected Oxidative Stress Parameters in the Tear Film

et al. 2019

View full text Add to dashboard Cite

show abstract

“…Bulbar conjunctival hyperemia and corneal/conjunctival were found to improve by using PF eye drops in our study as well as in other studies. Our research team and Misiuk-Hojlo et al [ 16 ] reported no improvement in tear breakdown time, while others reported significantly improved results [ 8 , 20 , 22 ]. The OSDI was significantly decreased in our study, and a previous study [ 20 ] presented similar results.…”

Section: Discussionmentioning

confidence: 66%

“…Therefore, there have been efforts to develop PF anti-glaucoma eye drops. In addition, studies comparing the effects of PF eye drops and conventional eye drops have been conducted in various countries [ 8 , 16 , 18 – 22 ]. In most studies, the effects of both eye-drops on IOP were similar, but PF eye drops tended to be more effective in reducing ocular surface symptoms and signs.…”

Section: Discussionmentioning

confidence: 99%

Efficacy and Safety of Preservative-free Latanoprost Eyedrops Compared with Preserved Prostaglandin Analogues in Patients with Open-angle Glaucoma

Seong

Lee

et al. 2021

Korean J Ophthalmol

View full text Add to dashboard Cite

Purpose To evaluate the safety and efficacy of preservative-free (PF) latanoprost in glaucoma patients. Methods In this prospective, open-label, observational study, a total of 27 primary open-angle glaucoma patients who used benzalkonium chloride-preserved prostaglandin analogues for at least 6 months were enrolled. After changing the eye drops to PF lataprost, the intraocular pressure (IOP) and ocular surface symptoms and signs were evaluated in all patients on days 0 (first visit, D0), 45 (D45), and 90 (D90). Results Mean IOP remained stable during the study period (14.0 ± 2.4 mmHg at D0, 13.9 ± 2.0 mmHg at D45, 13.7 ± 2.2 mmHg at D90; p = 0.603). Mean deviation, pattern standard deviation, and best-corrected visual acuity were similar before and after eye drops replacement. Bulbar conjunctival hyperemia, corneal staining, and conjunctival staining were significantly decreased over 90 days ( p = 0.025, p < 0.001, p = 0.020, respectively). The ocular surface disease index score showed a statistically significant improvement from 26.4 ± 18.5 at D0 to 19.8 ± 17.0 at D45 and 15.7 ± 15.6 at D90 ( p < 0.001). In the evaluation of ocular tolerability, burning symptoms and dryness were significantly decreased ( p = 0.001, p = 0.040). Conclusions The effects of PF latanoprost on reducing IOP were comparable with those of benzalkonium chloride-preserved prostaglandin analogues, but side effects on the ocular surface were much less pronounced when PF latanoprost was used. With this efficacy, PF latanoprost could slow the progression of glaucoma by increasing patient compliance.

show abstract

“…erefore, PF-tafluprost should be especially beneficial for patients with preexisting OSD. Several studies found that PF-latanoprost had an equivalent IOP-reducing efficacy compared to PC-latanoprost, although it was better tolerated [55,61]. Preservative-free eyedrops could possibly be the future development tendency for antiglaucoma drugs.…”

Section: Discussionmentioning

confidence: 99%

Analysis of the Responsiveness of Latanoprost, Travoprost, Bimatoprost, and Tafluprost in the Treatment of OAG/OHT Patients

Cai

Cao

Liu

et al. 2021

Journal of Ophthalmology

View full text Add to dashboard Cite

Aim. Within the clinical setting, some patients have been identified as lacking in response to PGAs. This meta-analysis study aimed to evaluate the responsiveness of latanoprost, travoprost, bimatoprost, and tafluprost in OAG/OHT patients, latanoprost nonresponders (LNRs), and the IOP-reducing efficacy and safety. Methods. A literature search was conducted on PubMed, Embase, and the Cochrane Controlled Trials Register. The primary clinical endpoint was the number of responders at the end of the study. The secondary clinical endpoint was the IOP reduction at the endpoint from baseline. Safety evaluation included five common adverse events: conjunctival hyperemia, hypertrichosis, ocular burning, ocular itching, and foreign-body sensation. Results. Eleven articles containing ten RCTs were included in this meta-analysis study. The results highlighted that, in the OAG/OHT population, there was no statistically significant difference in the responsiveness of the four PGAs. Bimatoprost had a better IOP-reducing efficacy than latanoprost. There was no significant difference in the IOP-reducing efficacy of travoprost, latanoprost, and tafluprost. In LNRs, the responsiveness of bimatoprost, travoprost, and latanoprost did not show statistical differences. Bimatoprost reduced IOP with a greater extent than latanoprost and travoprost in LNRs, while there was no significant difference in the IOP-reducing efficacy of travoprost and latanoprost. No serious adverse events occurred with the treatment of the four PGAs. The prevalence of conjunctival hyperemia due to bimatoprost or tafluprost was significantly higher than that of latanoprost. Other adverse events had no significant difference between the four drugs. Conclusion. The existing studies cannot prove that latanoprost, travoprost, bimatoprost, and tafluprost have different responsiveness in OAG/OHT patients. Switching to bimatoprost or travoprost cannot achieve a significant improvement in responsiveness in LNRs. Bimatoprost has a better IOP-reducing efficacy than latanoprost and travoprost. No serious adverse events occurred during treatment with any medication we studied.

show abstract

The RELIEF study: Tolerability and efficacy of preservative-free latanoprost in the treatment of glaucoma or ocular hypertension

Abstract: Preservative-free latanoprost has at least the same intraocular pressure-lowering efficacy as benzalkonium chloride-latanoprost, with a better tolerability profile. This may translate into greater control of treatment and improved quality of life.

Cited by 33 publications

References 24 publications

Effect of Topical Prostaglandin F2α Analogs on Selected Oxidative Stress Parameters in the Tear Film

Effect of Topical Prostaglandin F2α Analogs on Selected Oxidative Stress Parameters in the Tear Film

Efficacy and Safety of Preservative-free Latanoprost Eyedrops Compared with Preserved Prostaglandin Analogues in Patients with Open-angle Glaucoma

Analysis of the Responsiveness of Latanoprost, Travoprost, Bimatoprost, and Tafluprost in the Treatment of OAG/OHT Patients

Contact Info

Product

Resources

About